These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9400014)

  • 1. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice.
    Ohdo S; Makinosumi T; Ishizaki T; Yukawa E; Higuchi S; Nakano S; Ogawa N
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1383-8. PubMed ID: 9400014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics.
    Ohdo S; Inoue K; Yukawa E; Higuchi S; Nakano S; Ogawa N
    Jpn J Pharmacol; 1997 Nov; 75(3):283-90. PubMed ID: 9434260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
    Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
    Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian rhythm of irinotecan tolerability in mice.
    Filipski E; Lemaigre G; Liu XH; Méry-Mignard D; Mahjoubi M; Lévi F
    Chronobiol Int; 2004 Jul; 21(4-5):613-30. PubMed ID: 15470958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX; Hu ZP; Xu AL; Duan W; Zhu YZ; Huang M; Sheu FS; Zhang Q; Bian JS; Chan E; Li X; Wang JC; Zhou SF
    J Pharmacol Exp Ther; 2006 Oct; 319(1):82-104. PubMed ID: 16815871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonlinear pharmacokinetics of CPT-11 in rats.
    Kaneda N; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1721-5. PubMed ID: 2306726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.
    Araki E; Ishikawa M; Iigo M; Koide T; Itabashi M; Hoshi A
    Jpn J Cancer Res; 1993 Jun; 84(6):697-702. PubMed ID: 8340259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Res; 1996 Aug; 56(16):3752-7. PubMed ID: 8706020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
    Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
    Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse.
    Kaneda N; Nagata H; Furuta T; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1715-20. PubMed ID: 2306725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
    Khanna R; Morton CL; Danks MK; Potter PM
    Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
    Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
    J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
    Kawato Y; Aonuma M; Hirota Y; Kuga H; Sato K
    Cancer Res; 1991 Aug; 51(16):4187-91. PubMed ID: 1651156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles].
    Yang FY; Zhang WP; Wang XY; Yang WC; Dang HW
    Yao Xue Xue Bao; 2014 Jul; 49(7):1029-33. PubMed ID: 25233635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
    Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
    Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
    Morton CL; Wierdl M; Oliver L; Ma MK; Danks MK; Stewart CF; Eiseman JL; Potter PM
    Cancer Res; 2000 Aug; 60(15):4206-10. PubMed ID: 10945631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No toxicity caused by organ accumulation of CPT-11 on multiple injections under clinical regimens in rats.
    Miura K; Kaneko K; Kado S; Kurita A; Kaneda N; Chiba K; Kato I; Onoue M
    J Toxicol Sci; 2000 Dec; 25(5):393-402. PubMed ID: 11201170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of genistein, a natural soy isoflavone, on the pharmacokinetics and intestinal toxicity of irinotecan hydrochloride in rats.
    Yokooji T; Kawabe Y; Mori N; Murakami T
    J Pharm Pharmacol; 2013 Feb; 65(2):280-91. PubMed ID: 23278696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic characteristics of the novel anticancer agent CPT-11 and its active metabolite in plasma and lung lymph fluid following intravenous administration to sheep.
    Koizumi T; Kubo K; Hanaoka M; Miyahara T; Kaneki T; Yamamoto H; Ge RL; Fujimoto K; Kobayashi T; Sekiguchi M
    Arzneimittelforschung; 1998 Nov; 48(11):1097-100. PubMed ID: 9850432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.